Cell-targeted nucleic-acid and gene-editing delivery technologies

Technology
In development
University
Scouted & summarized by Halo AI

UT Southwestern Medical Center develops advanced non-viral delivery platforms, including Selective Organ Targeting (SORT) lipid nanoparticles, to enable precise, systemic delivery of genetic medicines like mRNA and CRISPR/Cas gene editors to targeted tissues and cells. The technology facilitates the next generation of genetic therapies for diseases ranging from cancer to genetic disorders, currently supported by research collaborations with industry partners.

Overview

UT Southwestern Medical Center is advancing a suite of RNA and gene-editing delivery technologies focused on overcoming the challenges of systemic administration. Through its Program in Genetic Drug Engineering, the center develops sophisticated delivery systems, including Selective Organ Targeting (SORT) lipid nanoparticles (LNPs). These synthetic carriers are engineered to transport genetic payloads—such as mRNA, siRNA, and CRISPR/Cas components—safely and precisely to specific tissues and cell types in vivo, extending therapeutic reach beyond the liver to organs like the lungs and spleen.

Technical specifications

The technology centers on the design of non-viral lipid nanoparticles that enhance the stability and intracellular delivery of fragile genetic medicines. Key capabilities and features include:

  • Selective Organ Targeting (SORT): A methodology that integrates supplemental molecules into LNP formulations to enable tissue-specific biodistribution and predictable delivery to extrahepatic tissues.
  • Modular Delivery Platforms: These systems support a wide variety of genetic cargoes, including mRNA, Cas9 ribonucleoproteins, and various guide RNAs, facilitating both transient protein expression and permanent gene correction.
  • Endosomal Escape Optimization: Engineering focuses on navigating critical barriers such as endosomal membrane destabilization to ensure efficient cytosolic release and, where necessary, nuclear entry of the cargo.
  • Broad Therapeutic Applicability: The platform is designed to support applications ranging from cancer therapy by disrupting oncogenic drivers to the treatment of genetic disorders such as muscular dystrophies and metabolic conditions.
Technology readiness level

The technology is currently at TRL 4-5. The underlying platforms, particularly the SORT LNP technology and the ability to perform in vivo CRISPR/Cas editing using synthetic nanoparticles, have been successfully validated through...

Generated Nov 12, 2026. Please verify key information.

About University of Texas Southwestern Medical Center

UT Southwestern Medical Center is a leading academic medical center within the University of Texas System, combining biomedical research, education, and a major clinical enterprise in Dallas. Co-located hospitals and outpatient networks provide direct access to clinicians, diverse patient populations, and real‑world data, enabling rapid design and execution of clinical studies. Companies engage through on‑campus incubator space, shared core facilities, and collaboration models that range from sponsored research to multi‑site trials. Research is supported primarily by NIH, with additional competitive federal awards from other national agencies. A dedicated technology transfer office streamlines IP protection, licensing, and startup formation to accelerate commercialization.

Halo home
Partner smarter. Move faster.
Get new partnering requests
delivered to your inbox.